Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - HospiMedica Asia (Singapore) September 2002:

This article was originally published in Clinica

Executive Summary

HospiMedica Asia will take place on September 10-12 2002 at the Suntec Singapore, Singapore. The 4th international exhibition on hospital, pharmaceutical, medical and rehabilitation equipment and supplies includes 300 exhibiting companies from 30 countries. The event comprises four sections: Asia-Invest, a business networking session initiated by the European Commission; the 2nd Parkway Medical Congress, a forum for the exchange of ideas, intelligence and developments in the healthcare industry; hospital tours offering insights into both private an government-run facilities; and new hospital projects showcase featuring hospitals that will be in operation over the next three years. Further details from Shirley Lim, on tel: +65 6332 9671; fax: +65 6337 4633; email: shirley@mda.com.sg www.hospimedica-asia.com

You may also be interested in...



Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Topics

UsernamePublicRestriction

Register

MT067554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel